[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

La Merie Publishing: Market Research Reports

Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.

The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.

Publications found: 223
Sort by:
Competitor Analysis: Cardiovascular Peptides US$ 383.00

Competitor Analysis: Cardiovascular Peptides The present Competitive Intelligence Report about Cardiovascular Peptides used to treat or prevcent heart failure, myocardial infarction, thrombosis, hypertension, peripheral vascular diseases, hemostasis and wound sealing provides a competitor evaluation in the ...

October 2014 59 pages
Competitor Analysis: Anti-Inflammatory Peptides US$ 319.00

Competitor Analysis: Anti-Inflammatory Peptides The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under ...

September 2014 44 pages
Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins US$ 255.00

Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins The present Competitive Intelligence Report about prophylaxis and therapy of Rabies ... virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

September 2014 33 pages
Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists US$ 469.00

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes ...

August 2014 71 pages
Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors US$ 272.00

Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors The present Competitive Intelligence Report about alpha1-proteinase inhibitors (alpha1-PI), alpha1-antitrypsin (AAT) and elastase inhibitors provides a competitor evaluation in the field of human ...

July 2014 32 pages
Botulinum Neurotoxins: A Comparative Industry Analysis Of Products, Pipelines, Technologies And Stakeholders US$ 2,656.00

Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders This business ... regarding botulinum neurotoxin engineering, modification and manufacturing. Chances and challenges for the stakeholders in the botulinum neurotoxin market are evaluated. The market for botulinum neurotoxin ...

July 2014 169 pages
Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors US$ 272.00

Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors The present Competitive Intelligence Reportabout phosphodiesterease 4 (PDE-4) Inhibitors provides a competitor evaluation in the field of mainly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of June 2010. ...

June 2014 34 pages
Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists US$ 136.00

Competitor Analysis: Kallikrein Inhibitors Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel approaches for prophylaxis and treatment of hereditary ...

June 2014 14 pages
Competitor Analysis: Cancer Vaccines US$ 1,112.00

... lines), microorganism-based and others. Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major ... . In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on: Drug ...

March 2014 179 pages
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors US$ 416.00

... and allow online work with the project data to print or export an individual report. With the approval and launch of next generation Her2 ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

February 2014 58 pages
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis US$ 2,873.00

... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...

January 2014 347 pages
Competitor Analysis: Immunocytokines US$ 334.00

... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...

January 2014 48 pages
Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors US$ 529.00

... developments in the pipeline of inhibitors of the janus-associated kinase (JAK) and of spleen tyrosine kinase provides a competitor evaluation in the field of active ... ) are made up of a family of four cytoplasmic tyrosine kinases—JAK1, JAK2, JAK3, and TYK2—that play pivotal roles in the signaling pathways ...

November 2013 69 pages
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives) US$ 662.00

... , proteins, peptides, vaccines and small molecules for prevention and treatment of Staphylococcus aureus infections. In addition, the report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: Drug ...

October 2013 92 pages
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry US$ 1,920.00

... new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks. This report entitled The ... and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products ...

October 2013 84 pages
Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors US$ 265.00

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

October 2013 33 pages
Competitor Analysis: Pim Kinase Inhibitors US$ 132.00

... and development of small molecule and siRNA/miRNA inhibitors of the Pim Kinases. In addition, the report lists company-specific R&D pipelines of Pim Kinase inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

September 2013 17 pages
Competitor Analysis: Wnt Pathway Inhibitors US$ 132.00

... antibody inhibitors of the Wnt ligand or its receptors Frizzled and LRP5/6 in oncology. In addition, the report lists company-specific R&D pipelines of Wnt pathway inhibitors. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...

September 2013 16 pages
Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors US$ 132.00

The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. ...

August 2013 13 pages
Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors US$ 132.00

The present Competitive Intelligence report about Focal Adhesion Kinase (FAK) Inhibitors provides a competitor evaluation in the field of small molecule-based ... and development of selective and multi-target small molecule Focal Adhesion Kinase (FAK) inhibitors in oncology. In addition, the report lists company ...

August 2013 13 pages
Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors US$ 199.00

The present Competitive Intelligence report about Anaplastic Lymphoma Kinase (ALK) Inhibitors provides a competitor evaluation in the field of small molecule and antibody-based inhibitors of Anaplastic Lymphoma Kinase (ALK) for the treatment of solid tumors as of August 2013. Purchase ...

August 2013 17 pages
Competitor Analysis: Smallpox Vaccines & Therapeutics US$ 199.00

The Competitive Intelligence report Smallpox Vaccines & Therapeutics as of August 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Variola virus infection and treatment of smallpox. Purchase of the pdf report includes a 6-month online ...

August 2013 20 pages
Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors US$ 199.00

The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule ... that repair DNA damage. Despite the recent failure of Sanofi’s PARP inhibitor iniparib, presentation of results from clinical studies with other ...

August 2013 22 pages
Protein Target & Pipeline Database: 1-Year Subscription US$ 1,588.00

... sources can be viewed and printed. Sales figures of major therapeutic proteins on the market are provided. An advanced search function allows to combine ... by e-mail within 24 hours after purchase. Benefits from the Protein Target & Pipeline Database: Intuitive use Designed for structured searches Focused ...

July 2013
Competitor Analysis ErbB / Her Receptor Antagonists US$ 853.00

... /Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy ... with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...

July 2013 168 pages
Competitor Analysis: c-MET/HGF Inhibitors US$ 394.00

The present Competitive Intelligence Report about Competitor Analysis: c-MET/HGF Inhibitors provides a competitor evaluation in the field of small molecule and ... HGF receptor) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for the treatment of solid tumors as of July 2013. Purchase of the ...

July 2013 57 pages
Competitor Analysis: Anthrax Vaccines & Therapeutics US$ 257.00

The Competitive Intelligence Report Anthrax Vaccines & Therapeutics as of June 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Bacillus anthracis infection and treatment of anthrax. Purchase of the pdf report includes a 6-month online ...

June 2013 32 pages
Recombinant Coagulation Factors 2013 - The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis US$ 2,767.00

... and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, ... of each major player in the field Downoad Sample Pages: Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: A ...

June 2013 129 pages
Competitive Information Service Package – 1-year subscription US$ 7,871.00

Competitive Information Service Package – 1-year subscription: Flat-Rate Access to La Merie Publishing Reports R&D Drug Pipeline Database R&D Pipeline News Subscription to this product provides access during one year to three Competitive Intelligence information products released by La Merie ...

May 2013
Competitor Analysis: Coagulation Factors US$ 800.00

The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access ...

May 2013 158 pages
Competitor Analysis: Thrombolytics & Fibrinolytics US$ 330.00

The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes ...

May 2013 38 pages
Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors US$ 2,100.00

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...

May 2013 301 pages
Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics US$ 322.00

The Competitive Intelligence Report Human Papilloma Virus (HPV) Vaccines & Therapeutics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel vaccines and therapeutics for prophylaxis of HPV infection and HPV-induced neoplasias and treatment of HPV-induced ...

May 2013 43 pages
Competitor Analysis: Antibody-Drug Conjugates (ADC) US$ 785.00

Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the ...

April 2013 104 pages
Competitor Analysis: Human Growth Hormone (hGH) US$ 395.00

Product description The Competitive Intelligence Report Human Growth Hormone (hGH) as of April 2013 provides a competitor analysis in the development pipeline of biosimilar versions of somatropin and next generation biobetter/biosuperior hGH products for treatment of growth hormone deficiency (GHD) in ...

April 2013 49 pages
Competitor Analysis: Erythropoiesis Stimulating Agents (ESA) US$ 650.00

... and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of ...

April 2013 94 pages
Competitor Analysis: Insulin US$ 590.00

Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and in...

April 2013 89 pages
Competitor Analysis: Interferon US$ 590.00

Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural...

April 2013 89 pages
Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis US$ 1,203.00

How do antibody characteristics impact clinical success? The analytical report 'Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis' evaluates the impact of a number of antibody attributes on the success rate of antibodies in clinical development. Among ...

March 2013 88 pages
Antibody Technologies and Attrition Rates - an Industry Analysis 2013 US$ 2,765.00

... legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to ... the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive ...

March 2013 607 pages
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART) US$ 335.00

... (ART) as of February 2013 provides a competitor analysis in the development pipeline of novel recombinant and purified FSH, hCG and LH receptor agonists for ... , the report lists company-specific R&D pipelines of FSH, LH and hCG products and projects. Competitor projects are listed in a tabular format providing ...

February 2013 43 pages
Competitor Analysis: Enzyme Replacement Therapies US$ 403.00

... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...

January 2013 74 pages
Competitor Analysis: Herpes Virus Vaccines and Therapeutics US$ 396.00

... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...

December 2012 56 pages
Competitor Analysis: Toll-like Receptor (TLR) Agonists & Antagonists US$ 910.00

... description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small ... with the project data to print or export an individual report. Toll-like receptors (TLRs) are a class of proteins that play a key role ...

December 2012 178 pages
Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors US$ 392.00

... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

November 2012 64 pages
Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists US$ 195.00

... Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report ...

October 2012 23 pages
Competitor Analysis: Pneumococcal and Streptococcal Vaccines US$ 260.00

... , Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...

October 2012 21 pages
Competitor Analysis: Tuberculosis Vaccines and Therapeutics US$ 516.00

... targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis. In addition, the report lists corporate and public R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action ...

September 2012 70 pages
Competitor Analysis: Malaria Vaccines & Therapeutics US$ 390.00

... description The present Competitive Intelligence Report about Malaria Vaccines & Therapeutics provides a competitor evaluation in the field of investigational small molecules and ... regions. Each year more than 350 million new cases of Malaria occur, it is one of the world’s most common diseases. People with ...

August 2012 64 pages
Competitor Analysis: CMV Vaccines & Therapeutics US$ 247.00

... approved for treatment or prevention of CMV disease, such as ganciclovir, or hyperimmune globulin preparations, but no specific CMV vaccine is approved. The present Competitor Analysis describes the R&D pipeline of new molecular entities including vaccines, monoclonal antibodies, peptides, cellular therapy ...

August 2012 23 pages

Filters

Search

Categories

2
1
1
4
1
19
27
3
2
1
10
4
21
5
5
100
17

Publishers

223

Regions

223

Price

Date

Pages

Offers

1
4